Vaxcyte is developing VAX-31 to prevent invasive pneumococcal disease (IPD) and pneumococcal pneumonia, two types of bacterial infections. In the Phase 3 trial, the vaccine met all prespecified ...
The company’s next-generation shot surpassed Wall Street’s expectations by matching the effectiveness of vaccines from Pfizer ...
Investigators analyzed 5 decades of clinical and genomic data to identify shifting trends in adult pneumococcal meningitis ...
Clinical Trials Arena on MSN
Vaxcyte’s stock up after pneumococcal vaccine proves non-inferiority
Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.
Key TakeawaysVaxcyte shares are up about 36% after its VAX-31 pneumococcal vaccine met every primary goal in OPUS-1, its pivotal adult Phase 3 trial. VAX-31 cleared a stricter-than-usual bar against ...
Shares in Vaxcyte have rocketed on the revelation of phase 3 trial data for its pneumococcal vaccine (PCV) candidate VAX-31, ...
VAX-31 beat Pfizer and Merck’s established pneumococcal conjugate vaccines in a Phase 3 trial, exceeding investors’ most ...
VAX-31 Met All Prespecified Primary Endpoints Across Age Groups Studied Compared to Prevnar 20® (PCV20) and/or Capvaxive® (PCV21) Prespecified ...
Vaxcyte disclosed that its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results